13 research outputs found
PND42 BRAZILIAN NATIONAL GUIDELINE FOR MULTIPLE SCLEROSIS (MS): AN EXPLORATORY STUDY ABOUT THE IMPACT OF THE PATIENT'S ADHERENCE IN THE TREATMENT COSTS
Get PDF
PND30 NATIONAL GUIDELINE FOR MULTIPLE SCLEROSIS TREATMENT IN BRAZILIAN PUBLIC HEALTH: AN ANALYSIS OF TREATMENT PATTERNS AND BUDGET IMPACT
Get PDFCS7 COST-EFFECTIVENESS AND BUDGET IMPACT OF INTRODUCING ROSUVASTATIN INTO THE BRAZILIAN NATIONAL DRUG FORMULARY
Get PDFPRS2 BUDGET IMPACT ANALYSIS OF INTRODUCTION FLUTICASONE PROPIONATE/SALMETEROL (500/50 MG) INTO THE BRAZILIAN NATIONAL DRUG FORMULARY
No full text
PSS10 COST-EFFECTIVENESS OF ANTIVEGF THERAPIES FOR WET AGE-RELATED MACULAR DEGENERATION—AMD IN BRAZIL: THE PRIVATE PAYER PERSPECTIVE
No full textPND30 NATIONAL GUIDELINE FOR MULTIPLE SCLEROSIS TREATMENT IN BRAZILIAN PUBLIC HEALTH: AN ANALYSIS OF TREATMENT PATTERNS AND BUDGET IMPACT
No full textPMS9 COST-MINIMIZATION ANALYSIS OF VISCOSUPPLEMENTATION TREATMENT OSTEOARTHRITIS OF KNEE IN BRAZIL'S PRIVATE SECTOR
No full textPRS6 COST-EFFECTIVENESS OF FLUTICASONE PROPIONATE/SALMETEROL (500/50 MG) IN THE TREATMENT OF COPD IN BRAZILIAN PUBLIC SECTOR
No full text
